Sanofi and QuantHealth Team up to Advance AI-Powered Digital Twins and Clinical Trials

赛诺菲与QuantHealth合作推进人工智能驱动的数字孪生和临床试验

Simulations to Accelerate Drug Development

加速药物开发的模拟技术

QuantHealth

量健康

, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from

，一家人工智能驱动的临床试验模拟领域的先驱，宣布获得了来自的战略投资

Sanofi Ventures

赛诺菲风险投资

, the venture capital arm of global healthcare leader Sanofi. The investment will accelerate QuantHealth’s efforts to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development, bringing its total funds raised to $30 million.

，全球医疗保健领导者赛诺菲的风险投资部门。该投资将加速 QuantHealth 将可扩展的患者级模拟和数字孪生技术推向药物开发前沿的努力，使其筹集的总资金达到 3000 万美元。

QuantHealth’s platform enables pharmaceutical companies to virtually simulate clinical trials using real-world data and advanced AI models. By generating millions of patient-level digital twins, the platform predicts trial outcomes and optimizes protocol design, aiming to improve trial success rates, timelines, and cost efficiency..

QuantHealth的平台使制药公司能够使用真实世界的数据和先进的人工智能模型虚拟模拟临床试验。通过生成数百万个患者级别的数字孪生，该平台预测试验结果并优化方案设计，旨在提高试验成功率、缩短时间线并提升成本效益。

The investment has further catalyzed an enterprise strategic relationship that supports Sanofi’s focus on integrating advanced AI and digital technologies to drive transformation across its R&D ecosystem. As part of the investment, Cris De Luca, Partner at Sanofi Ventures, will join as an observer on QuantHealth’s Board of Directors..

这项投资进一步催化了支持赛诺菲专注于整合先进人工智能和数字技术以推动其研发生态系统转型的企业战略关系。作为投资的一部分，赛诺菲风投的合伙人克里斯·德·卢卡将作为观察员加入量康董事会。

“We’re proud to welcome Sanofi Ventures as an investor and strategic ally in our journey,” said Orr Inbar, Co-Founder and CEO at QuantHealth. “Sanofi is at the forefront of digital transformation in pharma, and this relationship will help us scale our impact and bring more predictive, AI-driven approaches to clinical development.”.

“我们很自豪地欢迎赛诺菲风险投资公司作为我们在这一旅程中的投资者和战略盟友，”QuantHealth的联合创始人兼首席执行官奥尔·因巴尔表示。“赛诺菲处于制药行业数字化转型的前沿，这一合作关系将帮助我们扩大影响力，并为临床开发带来更多基于预测和人工智能的方法。”

“QuantHealth has the potential to transform how clinical trials are designed and optimized,” said Cris De Luca, Partner at Sanofi Ventures. “Their approach to leveraging digital twins and real-world data is advancing the next generation of R&D, and I look forward to supporting the team.”

“QuantHealth 有潜力改变临床试验的设计和优化方式，”赛诺菲风险投资公司合伙人克里斯·德·卢卡表示。“他们利用数字孪生和真实世界数据的方法正在推动下一代研发，我期待支持这个团队。”

“At Sanofi, we are building an AI-first organization, and engaging with innovators like QuantHealth is central to our strategy,” said Emmanuel Frenehard, Chief Digital Officer at Sanofi. “Their platform represents an important opportunity to reimagine clinical trial design through simulation, and we’re excited to explore this capability together.”.

“在赛诺菲，我们正在建立一个以人工智能为先的组织，与QuantHealth这样的创新者合作是我们战略的核心，”赛诺菲首席数字官Emmanuel Frenehard表示。“他们的平台通过模拟重新构想临床试验设计带来了重要的机会，我们很期待共同探索这一能力。”

This investment and enterprise relationship underscores a shared commitment to advancing drug development through the responsible use of artificial intelligence in life sciences.

这项投资与企业关系凸显了通过在生命科学领域负责任地使用人工智能来推动药物开发的共同承诺。

About QuantHealth

关于QuantHealth

QuantHealth is an AI-driven clinical trial simulation company that helps pharmaceutical companies design faster, more successful trials using real-world data and predictive modeling. With access to over 350 million patient records and proprietary AI algorithms, QuantHealth’s platform simulates trials at scale to optimize protocols, reduce risk, and accelerate timelines..

QuantHealth是一家由人工智能驱动的临床试验模拟公司，利用真实世界数据和预测建模帮助制药公司设计更快、更成功的试验。通过访问超过3.5亿份患者记录和专有的人工智能算法，QuantHealth的平台大规模模拟试验，以优化方案、降低风险并加速时间表。

About Sanofi Ventures

关于赛诺菲风险投资

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing globally in early-stage biotech and digital health companies aligned with Sanofi’s mission to chase the miracles of science. Areas of focus include immunology, oncology, rare diseases, vaccines, and digital innovation.

Sanofi Ventures赛诺菲的企业风险投资部门，负责在全球范围内投资与赛诺菲追求科学奇迹使命相符的早期生物技术和数字健康公司。重点关注领域包括免疫学、肿瘤学、罕见病、疫苗和数字创新。